{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T15:58:00Z","timestamp":1776614280145,"version":"3.51.2"},"reference-count":34,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.3892\/or.2014.3049","type":"journal-article","created":{"date-parts":[[2014,2,24]],"date-time":"2014-02-24T09:51:59Z","timestamp":1393235519000},"page":"1683-1690","source":"Crossref","is-referenced-by-count":29,"title":["Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients"],"prefix":"10.3892","volume":"31","author":[{"given":"YASUTO","family":"AKIYAMA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MASARU","family":"KOMIYAMA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HARUO","family":"MIYATA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MIKA","family":"YAGOTO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TADASHI","family":"ASHIZAWA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AKIRA","family":"IIZUKA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHIE","family":"OSHITA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AKIKO","family":"KUME","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MASAHIRO","family":"NOGAMI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ICHIRO","family":"ITO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"REIKO","family":"WATANABE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TAKASHI","family":"SUGINO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KOICHI","family":"MITSUYA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NAKAMASA","family":"HAYASHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YOKO","family":"NAKASU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KEN","family":"YAMAGUCHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2014,2,24]]},"reference":[{"key":"key20180107222433_b1-or-31-04-1683","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"key20180107222433_b2-or-31-04-1683","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2005.04.5963","article-title":"Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981\/22981-NCIC CE3 phase III randomized trial","volume":"24","author":"Mirimanoff","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20180107222433_b3-or-31-04-1683","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.stem.2009.08.018","article-title":"Autocrine TGF-\u03b2 signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors","volume":"5","author":"Ikushima","year":"2009","journal-title":"Cell Stem Cell"},{"key":"key20180107222433_b4-or-31-04-1683","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1158\/1535-7163.MCT-11-0480","article-title":"Therapeutic potential of AZD1480 for the treatment of human glioblastoma","volume":"10","author":"McFarland","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"key20180107222433_b5-or-31-04-1683","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11060-011-0786-z","article-title":"Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2\/STAT3 pathway","volume":"107","author":"Sai","year":"2012","journal-title":"J Neurooncol"},{"key":"key20180107222433_b6-or-31-04-1683","first-page":"1245","article-title":"Antitumor activity of a novel small molecules STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation","volume":"38","author":"Ashizawa","year":"2011","journal-title":"Int J Oncol"},{"key":"key20180107222433_b7-or-31-04-1683","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1756-9966-29-138","article-title":"Analysis of the expression profile of Dickkopf-1 gene in human glioma and the association with tumor malignancy","volume":"29","author":"Zhou","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"key":"key20180107222433_b8-or-31-04-1683","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1200\/JCO.2008.16.7510","article-title":"Randomized phase II study of cilemgitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme","volume":"26","author":"Reardon","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180107222433_b9-or-31-04-1683","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1586\/ern.12.53","article-title":"Angiogenic inhibition in high-grade gliomas: past, present and future","volume":"12","author":"Jo","year":"2012","journal-title":"Expert Rev Neurother"},{"key":"key20180107222433_b10-or-31-04-1683","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jocn.2010.11.034","article-title":"A phase I\/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma","volume":"18","author":"Chang","year":"2011","journal-title":"J Clin Neurosci"},{"key":"key20180107222433_b11-or-31-04-1683","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2174\/157488708783330530","article-title":"Dendritic cell immunotherapy for malignant gliomas","volume":"3","author":"Luptrawan","year":"2008","journal-title":"Rev Recent Clin Trials"},{"key":"key20180107222433_b12-or-31-04-1683","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00262-012-1261-1","article-title":"Intergation of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I\/II trial","volume":"61","author":"Ardon","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"key20180107222433_b13-or-31-04-1683","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11060-010-0131-y","article-title":"Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study","volume":"99","author":"Ardon","year":"2010","journal-title":"J Neurooncol"},{"key":"key20180107222433_b14-or-31-04-1683","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1349-7006.2004.tb02188.x","article-title":"Overexpression of the Wilms\u2019 tumor gene WT1 in primary astrocytic tumors","volume":"95","author":"Oji","year":"2004","journal-title":"Cancer Sci"},{"key":"key20180107222433_b15-or-31-04-1683","first-page":"583","article-title":"MAGE-1, a cancer\/testis-antigen, expression in childhood astrocytomas as an indicator of tumor progression","volume":"16","author":"Bodey","year":"2002","journal-title":"In vivo"},{"key":"key20180107222433_b16-or-31-04-1683","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1158\/0008-5472.CAN-03-3504","article-title":"HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells","volume":"64","author":"Liu","year":"2004","journal-title":"Cancer Res"},{"key":"key20180107222433_b17-or-31-04-1683","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/BF03401786","article-title":"Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer\/testis antigen","volume":"6","author":"Debinski","year":"2000","journal-title":"Mol Med"},{"key":"key20180107222433_b18-or-31-04-1683","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ijc.10170","article-title":"Analysis of the antibody repertoire of astrocytoma patients against antigens expressed by gliomas","volume":"98","author":"Schmits","year":"2002","journal-title":"Int J Cancer"},{"key":"key20180107222433_b19-or-31-04-1683","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/mc.20614","article-title":"Enhanced expression of cancer testis antigen genes in glioma stem cells","volume":"49","author":"Yawata","year":"2010","journal-title":"Mol Carcinog"},{"key":"key20180107222433_b20-or-31-04-1683","first-page":"7","article-title":"Cancer-testis (CT) antigen expression in medulloblastoma","volume":"8","author":"Oba-Shinjo","year":"2008","journal-title":"Cancer Immun"},{"key":"key20180107222433_b21-or-31-04-1683","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jocn.2011.10.008","article-title":"Cancer-testis and melanocyte-differentiation antigen expression in malignant glioma and meningioma","volume":"19","author":"Syed","year":"2012","journal-title":"J Clin Neurosci"},{"key":"key20180107222433_b22-or-31-04-1683","first-page":"3916","article-title":"Expression of cancer testis genes in human brain tumors","volume":"6","author":"Sahin","year":"2000","journal-title":"Clin Cancer Res"},{"key":"key20180107222433_b23-or-31-04-1683","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s002620000169","article-title":"A listing of human tumor antigens recognized by T cells","volume":"50","author":"Renkvist","year":"2001","journal-title":"Cancer Immunol Immunother"},{"key":"key20180107222433_b24-or-31-04-1683","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","article-title":"Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells","volume":"4","author":"Nestle","year":"1998","journal-title":"Nat Med"},{"key":"key20180107222433_b25-or-31-04-1683","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1479-5876-3-4","article-title":"Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells","volume":"3","author":"Akiyama","year":"2005","journal-title":"J Transl Med"},{"key":"key20180107222433_b26-or-31-04-1683","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3816\/CLC.2009.n.052","article-title":"MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy","volume":"10","author":"Tyagi","year":"2009","journal-title":"Clin Lung Cancer"},{"key":"key20180107222433_b27-or-31-04-1683","doi-asserted-by":"crossref","first-page":"6854","DOI":"10.1016\/j.vaccine.2009.09.018","article-title":"Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432","volume":"27","author":"Aoki","year":"2009","journal-title":"Vaccine"},{"key":"key20180107222433_b28-or-31-04-1683","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/JCO.2010.30.7744","article-title":"Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with \u03b1-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma","volume":"29","author":"Okada","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180107222433_b29-or-31-04-1683","first-page":"2143","article-title":"Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas","volume":"150","author":"Chi","year":"1997","journal-title":"Am J Pathol"},{"key":"key20180107222433_b30-or-31-04-1683","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"key20180107222433_b31-or-31-04-1683","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2007.11.5964","article-title":"Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity","volume":"26","author":"Hegi","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180107222433_b32-or-31-04-1683","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.2008.18.8417","article-title":"Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant maliganant glioma","volume":"27","author":"Quinn","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180107222433_b33-or-31-04-1683","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1002\/ijc.23407","article-title":"The DNA demethylating agent 5-aza-2\u2032-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma","volume":"122","author":"Natsume","year":"2008","journal-title":"Int J Cancer"},{"key":"key20180107222433_b34-or-31-04-1683","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1177\/1087057110374983","article-title":"Knockdown of cancer testis antigens modulates neural stem cell marker expression in glioblastoma tumor stem cells","volume":"15","author":"Low","year":"2010","journal-title":"J Biomol Screen"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2014.3049\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T22:27:28Z","timestamp":1565216848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2014.3049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,24]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,2,24]]},"published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.3892\/or.2014.3049"],"URL":"https:\/\/doi.org\/10.3892\/or.2014.3049","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,24]]}}}